Abstract:ABSTRACT The use of antidepressants during the third trimester of pregnancy has been implicated in the development of persistent pulmonary hypertension of the newborn (PPHN), which is known to cause substantial morbidity and mortality in infants. However, in 2011, the Food and Drug Administration noted that the findings on this issue were still premature, causing great controversy and concern. To address this issue, the authors of the present study examined whether antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and non-SSRIs, increased the risk of PPHN development in infants. The authors evaluated the records of 128,950 women (12–55 years of age) who were exposed to an antidepressant, defined as filling 1 prescription of either an SSRI or a non-SSRI, during the 90 days before delivery of a live-born infant. Maternal and infant dataset records were extracted from the from the Medicaid Analytic eXtract database based on International Classification of Diseases, Ninth Revision, Clinical Modification diagnostic codes for persistent fetal circulation (747.83) or primary pulmonary hypertension (416.0x). Data were analyzed using both nonadjusted and adjusted logistic regression models, to account for different levels of confounding factors. A sensitivity analysis was also included, to account for potential exposure misclassification, wherein exposure was redefined as filling 2 prescriptions instead of 1. Infants exposed to antidepressants during the last 90 days of pregnancy, especially to SSRI antidepressants, were at statistically significantly higher risk for PPHN development when compared with unexposed infants (31.5 per 10,000 SSRI-exposed neonates, 29.1 per 10,000 non–SSRI-exposed neonates, and 20.8 per 10,000 unexposed infants). In the depression-restricted adjusted analysis, results showed that 33.8 SSRI-exposed, 34.4 non–SSRI-exposed, and 24.9 unexposed infants per 10,000 infants developed PPHN. For SSRI-exposed women, odds ratios were 1.51 (95% confidence interval [CI], 1.35–1.69; unadjusted) and 1.10 (95% CI, 0.94–1.29; depression diagnosis and propensity score adjusted). For non–SSRI-exposed women, odds ratios were 1.40 (95% CI, 1.12–1.75; unadjusted) and 1.02 (95% CI, 0.77–1.35; depression diagnosis and propensity score adjusted). No association was found between SSRI or non-SSRI antidepressants and severe PPHN. Sensitivity analysis did not yield significant differences between patients filling 1 prescription and patients filling 2 prescriptions. The results of this study support previous findings that there is potentially increased risk of PPHN associated with antidepressant use in late pregnancy. However, the authors found that after adjusting for depression and other confounding factors, the magnitude of risk is smaller than previously reported and was not statistically significant with either non-SSRI antidepressant use or SSRI antidepressant use.

Fetal ductal constriction caused by SSRI: A case report

Sudden Onset of Severe Pulmonary Hypertension in a Preterm Infant: A Case Report on the Role of Maternal Use of Serotonin Re-Uptake Inhibitors During Pregnancy and Concurrent Risk Factors

Foetal ductus arteriosus constriction unrelated to non-steroidal anti-Inflammatory drugs: a case report and literature review

Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis

Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose

Fetal ductus arteriosus constriction and closure: analysis of the causes and perinatal outcome related to 45 consecutive cases

Selective Serotonin Reuptake Inhibitors and Persistent Pulmonary Hypertension of the Newborn: An Update Meta-Analysis

Sertraline-Induced 5-HT Dysregulation in Mouse Cardiomyocytes and the Impact on Calcium Handling

Citalopram and sertraline exposure compromises embryonic bone development

Maternal treatment with selective serotonin reuptake inhibitors during pregnancy and delayed neonatal adaptation: a population-based cohort study

Maternal use of selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn

Prenatal exposure to sertraline, associated or not with stress, can negatively program somatic and neurobehavioral development of female rats, and dysregulate reproductive function in adulthood

A population pharmacokinetic model for sertraline in women during the perinatal period—A contribution from the ConcePTION project

Case Report: Persistent Pulmonary Hypertension of the Newborn and Narrowing of the Ductus Arteriosus After Topical Use of Non-Steroidal Anti-Inflammatory During Pregnancy

Fetal Ductus Arteriosus Premature Constriction An Analysis of 22 Cases

Is lactational Sertraline exposure safe for maternal health and the reproductive/neurobehavioral development of the descendants? A study in rats.

Timing of selective serotonin reuptake inhibitor use and risk for preterm birth and related adverse events: with a consideration of the COVID-19 pandemic period

Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn

Sildenafil citrate for the management of fetal growth restriction and oligohydramnios

Characteristics of breastfeeding newborns in the first month of life with in utero selective serotonin reuptake inhibitor medication exposure: a scoping review protocol

Dose-dependent increase in risk of bleeding and bleeding complications in relation to SSRI use at delivery